ACHI Achiko AG

Achiko AG Announces Corporate Update Webcast

Achiko AG / Key word(s): Miscellaneous
Achiko AG Announces Corporate Update Webcast

16.11.2022 / 16:20 CET/CEST


 Achiko AG Announces Corporate Update Webcast

Commercial Delivery of its Saliva-Based Covid-19 Test AptameXTM Has Commenced

Zurich, 16 November 2022: Ad hoc announcement pursuant to Art. 53 LR – (SIX: ACHI; OTCQB:  ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) a healthcare technology company that is developing new innovations and disruptive diagnostic solutions that put people first announced today that it will hold a corporate update webcast for all shareholders and investors on Tuesday, November 22, 2022 at 3.00pm CET/9.00am EST. A PowerPoint presentation will be available at the time of the call and published on the company website at .

Details of the webcast are as follows:


Date:                  22 November 2022
Time:                  3.00pm CET / 9.00am EST
Format:              Zoom Call
Presenter:         Mr Steven Goh, CEO of Achiko AG
Meeting link:    
Meeting ID:       984 0412 3755
Passcode:         achiko

Find your local number:
 

Recently, Achiko that it is commencing commercial deliveries of its Generation 2 ™ Covid-19 test kit to Nahdlatul Ulama and other commercial clients, both starting in and around Jakarta.  Nahdlatul Ulama is the Jakarta branch of Nahdlatul Ulama, which nationally in Indonesia has over 90 million registered members and operates over 6,000 schools and universities, and several hundred hospitals and clinics.

AptameX is the Company’s proprietary saliva-based Covid-19 test utilising DNA aptamers bound to gold nanoparticles in a colloidal solution.  The result is read by a UV Spectrophotometer and then analysed with custom software.  Unlike a molecular and immunoassay approaches, the test’s use of DNA aptamers has yielded encouraging results at low viral loads outperforming most lateral flow based rapid tests.

 

ABOUT ACHIKO AG 

Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that put people first. The Company’s lead product, AptameX™, is a rapid, reliable Covid-19 test with a companion app, Teman Sehat™, offering a user-friendly digital health passport.  AptameX™ and Teman Sehat™ were launched in Indonesia in mid-2021 and AptameX™ received the CE Mark in the European Union in May 2022.  

The AptameX™ DNA aptamer tests can be rapidly chemically synthesised, are cost-effective, easily scalable and have broad potential across multiple disease areas. Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of diseases in the rapidly evolving healthcare diagnostics field.  

Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world. 

 

Media contacts:  

ACHIKO AG

E:

Switzerland & Global
Marcus Balogh
Farner Consulting Ltd
E:
T: 7


Disclaimer 
This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise



End of Media Release


Language: English
Company: Achiko AG
Tessinerplatz 7
8002 Zurich
Switzerland
E-mail:
Internet: /
ISIN: CH0522213468
Valor: 48788430
Listed: SIX Swiss Exchange
EQS News ID: 1489695

 
End of News EQS News Service

1489695  16.11.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1489695&application_name=news&site_id=research_pool
EN
16/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Achiko AG

 PRESS RELEASE

Achiko AG Production and Sales Update

Achiko AG Production and Sales Update AptameX™ Gen 2 Covid-19 rapid calibration outperforms Abbott Pan Bio and Clugene’s rapid tests in Indonesia in validation tests.Sample of 20 PCR Positive and 9 Negative samples, indicated a 100% match between AptameX™ Gen 2 product to PCR, whilst Clungene and Abbott’s Pan Bio were between 6% and 50% sensitive only.Achiko remains committed to sales and is resolving production issues. ZURICH, Switzerland, Dec. 21, 2022 (GLOBE NEWSWIRE) --  Ad hoc announcement pursuant to Art. 53 LR – (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Compa...

 PRESS RELEASE

2022 Ordinary Shareholders’ Meeting of Achiko AG: Shareholders Adopt A...

2022 Ordinary Shareholders’ Meeting of Achiko AG: Shareholders Adopt All Proposals ZURICH, Switzerland, Dec. 20, 2022 (GLOBE NEWSWIRE) -- (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) held its Annual General Meeting today at 10:00 CET in Zurich. Due to the Covid-19 pandemic, this Annual General Meeting was held without the physical presence of the shareholders in accordance with art. 27 para. 1 letter b of the Covid-19-Ordinance 3. Shareholders exercised their shareholder rights through an independent proxy. Achiko is pleased to announce that all resolutions w...

 PRESS RELEASE

Ordentliche Generalversammlung 2022 der Achiko AG: Aktionäre nehmen al...

Achiko AG / Schlagwort(e): Generalversammlung Ordentliche Generalversammlung 2022 der Achiko AG: Aktionäre nehmen alle Anträge an 20.12.2022 / 18:00 CET/CEST  Ordentliche Generalversammlung 2022 der Achiko AG: Aktionäre nehmen alle Anträge an Zurich, 20 December 2022: Corporate News – (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) ("Achiko", die "Gesellschaft") hat heute um 10:00 MEZ in Zürich ihre ordentliche Generalversammlung abgehalten. Aufgrund der Covid-19 Pandemie fand diese Generalversammlung ohne physische Anwesenheit der Aktionäre gemäss Art. 27 Abs. 1 Buchstabe b ...

 PRESS RELEASE

2022 Ordinary Shareholders’ Meeting of Achiko AG: Shareholders adopt a...

Achiko AG / Key word(s): AGMEGM 2022 Ordinary Shareholders’ Meeting of Achiko AG: Shareholders adopt all proposals 20.12.2022 / 18:00 CET/CEST 2022 Ordinary Shareholders’ Meeting of Achiko AG: Shareholders adopt all proposals Zurich, 20 December 2022: Corporate News – (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) held its Annual General Meeting today at 10:00 CET in Zurich.  Due to the Covid-19 pandemic, this Annual General Meeting was held without physical presence of the shareholders in accordance with art. 27 para. 1 letter b of the Covid-19-Or...

 PRESS RELEASE

Achiko AG Issues a Convocation Notice to its Shareholders for its Annu...

Achiko AG Issues a Convocation Notice to its Shareholders for its Annual General Meeting on December 20, 2022 ZURICH, Switzerland, Nov. 25, 2022 (GLOBE NEWSWIRE) -- (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) has issued a convocation notice to its shareholders for the Company's Annual General Meeting taking place at 10:00 a.m. CET on December 20, 2022, in the offices of the Notary public Notariat Riesbach-Zurich, Kreuzstrasse 42, 8008 Zurich Zurich. Due to the Covid-19 pandemic, this year’s Annual General Meeting will be held in accordance with art. 27 para. 1...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch